G. Chiriacò

Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.

D. Generali, G. Roviello, C. Pacifico, 2017, Critical reviews in oncology/hematology.

Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer

A. D’Angelo, R. Petrioli, G. Roviello, 2020, Anti-cancer drugs.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer

D. Generali, R. Petrioli, G. Roviello, 2018, Oncotarget.

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

G. Francini, E. Francini, A. Pascucci, 2011, British Journal of Cancer.

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer

R. Petrioli, G. Roviello, M. Aieta, 2019, Investigational New Drugs.

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

E. Francini, A. Pascucci, A. Manganelli, 2011, Prostate cancer.